Morinidazole
Morinidazole was approved by China Food and Drug Administration (CFDA) on February 24, 2014. It was developed and marketed as 迈灵达® by Hansoh Pharmaceutical.
Morinidazole is a nitroimidazoles antibiotic indicated for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria.
迈灵达® is available as 100ml solution for intravenous injection, containing 0.5 g of free Morinidazole. The recommended dose is 500 mg (100 mL injection) twice daily every 6-8 hours continuously for 5-7 days.
General Information
Update Date：2016-03-14
- Drug Name：
- Morinidazole
- Research Code：
- Trade Name：
- 迈灵达®
- MOA：
- Nitroimidazoles antibiotic
- Indication：
- Pelvic inflammatory disease; Appendicitis
- Status：
- Approved
- Company：
- Hansoh (Originator)
- Sales：
- ATC Code：
Approved Countries or Area
Update Date：2015-07-29
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2014-02-24 | Marketing approval | 迈灵达 | Pelvic inflammatory disease,Appendicitis | Injection | 0.5 g Morinidazole per 100 mL | Hansoh |
Chemical Structure
Update Date：2015-08-27
|
Molecular Weight | 270.29 | ||||||||||||
| Formula | C11H18N4O4 | |||||||||||||
| CAS No. | 92478-27-8 (Morinidazole); | |||||||||||||
| Chemical Name | 1-(2-methyl-5-nitro-1H-imidazol-1-yl)-3-morpholinopropan-2-ol | |||||||||||||
| Morinidazole （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Related Patents
Update Date：2015-08-31
Synthesis & Impurities
Update Date：2016-02-01
